Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results)

被引：0
|
作者：
Vermersch, P. [1 ]
Eralinna, J. [2 ]
Nicholas, R. [3 ,4 ]
Oreja-Guevara, C. [5 ]
Siva, A. [6 ]
Van Wijmeersch, B. [7 ,8 ]
Wiendl, H. [9 ]
Buffels, R. [10 ]
Wei, W. [10 ]
Comi, G. [11 ]
机构：
[1] Univ Lille, Lille, France
[2] NEO Res, Turku, Finland
[3] Imperial Coll Healthcare NHS Trust, London, England
[4] Imperial Coll, London, England
[5] Hosp Clin San Carlos, Madrid, Spain
[6] Istanbul Univ, Cerrahpasa Fac Med, Cerrahpasa, Turkey
[7] Univ Hasselt, Overpelt, Belgium
[8] Rehabil & MS Ctr, Overpelt, Belgium
[9] Univ Munster, Munster, Germany
[10] F Hoffmann Roche Ltd, Basel, Switzerland
[11] Univ Vita Salute San Raffaele, Milan, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P035
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results)
    Vermersch, P.
    Eralinna, J. -P.
    Nicholas, R.
    Oreja-Guevara, C.
    Siva, A.
    Van Wijmeersch, B.
    Wiendl, H.
    Buffels, R.
    Kuhelj, R.
    Wei, W.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 344 - 345
  • [2] Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results)
    Vermersch, P.
    Eralinna, J. P.
    Nicholas, R.
    Oreja-Guevara, C.
    Siva, A.
    Van Wijmeersch, B.
    Wiendl, H.
    Buffels, R.
    Kuhelj, R.
    Wei, W.
    Comi, G.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [3] Efficacy and safety of ocrelizumab in patients with RRMS with suboptimal response to prior disease-modifying therapies: 3-year data from CASTING and LIBERTO 1-year interim results
    Van Wijmeersch, B.
    Comi, G.
    Oreja-Guevara, C.
    Wiendl, H.
    Wuerfel, J.
    Buffels, R.
    Dirks, P.
    Kuenzel, T.
    Kadner, K.
    Vermersch, P.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 543 - 544
  • [4] One-year interim analysis results of the Phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had suboptimal response with prior disease-modifying treatments
    Leist, Thomas
    Reder, Anthony
    Bermel, Robert
    Weinstock-Guttman, Bianca
    Freedman, Mark
    Cutter, Gary
    Stankiewicz, James
    Ma, Xiaoye
    Musch, Bruno
    Csoboth, Csilla
    Wolinsky, Jerry
    NEUROLOGY, 2019, 92 (15)
  • [5] EFFICACY AND SAFETY OF DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: A SYSTEMATIC REVIEW
    Lingohr-Smith, M.
    Deitelzweig, C.
    Lin, G.
    Lin, J.
    VALUE IN HEALTH, 2021, 24 : S158 - S158
  • [6] The efficacy and safety of oral disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review
    Shahtaheri, Rahil Sadat
    Nikfar, Shekoufeh
    Khorasani, Elahe
    Sabbagh-Baniazad, Mansoureh
    Goudarzi, Zahra
    Emamikhah, Maziar
    CURRENT JOURNAL OF NEUROLOGY, 2020, 19 (03): : 138 - 145
  • [7] Effectiveness and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis who had a suboptimal response with prior disease-modifying therapy: 2-year findings from CHORDS
    Weinstock-Guttman, B.
    Bermel, R.
    Csoboth, C.
    Cutter, G.
    Freedman, M.
    Leist, T. P.
    Ma, X.
    Musch, B.
    Reder, A.
    Stankiewicz, J.
    Wolinsky, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 43 - 43
  • [8] Pregnancy and disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
    Oztekin, N. S.
    Oztekin, M. F.
    MULTIPLE SCLEROSIS, 2006, 12 : S95 - S96
  • [9] Baseline characteristics of the CASTING Study population: a Phase IIIB Trial evaluating Ocrelizumab in patients with relapsing-remitting Multiple Sclerosis and suboptimal response to disease-modifying therapies
    Vermersch, P.
    Comi, G.
    Siva, A.
    Oreja-Guevara, C.
    Wiendl, H.
    Van Wijmeersch, B.
    Eralinna, J. -P.
    Nicholas, R.
    Buffels, R.
    Bernasconi, C.
    Kuhelj, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 190 - 190
  • [10] Two-year results of the Phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had a suboptimal response with prior disease-modifying therapy
    Weinstock-Guttman, Bianca
    Bermel, Robert
    Csoboth, Csilla
    Cutter, Gary
    Freedman, Mark
    Leist, Thomas
    Ma, Xiaoye
    Musch, Bruno
    Reder, Anthony
    Stankiewicz, James
    Wolinsky, Jerry
    NEUROLOGY, 2020, 94 (15)
12345